PDCD1 and non-small cell lung carcinoma: Yang et al. reported that in NSCLC patients receiving various PD-1 inhibitors combined with platinum-based chemotherapy (n = 79), patients achieving CR/PR/SD exhibited significantly higher baseline proportions of CD4+ T cells, and high levels of CD4+ T cells before and after treatment were positively correlated with OS and PFS [113].